Aim: To evaluate the potential for semaglutide to help people with type 2 diabetes (T2D) achieve glycated haemoglobin (HbA1c) targets while avoiding unwanted outcomes, such as weight gain, hypoglycaemia and gastrointestinal (GI) side effects.
| INTRODUCTION
Type 2 diabetes (T2D) is a chronic disease characterized by insulin resistance and a progressive decline in β-cell function. 1 Initial management of T2D involves lifestyle changes and monotherapy with metformin. 1, 2 Often, however, as glycaemic control deteriorates, combination therapy with other oral antidiabetic drugs (OADs) is required, with or without injectable therapies such as insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs).
1,2
The optimum treatment for T2D should involve patient-oriented treatment goals that extend beyond glycated haemoglobin (HbA1c)
reduction alone, such as minimizing the risk of unwanted effects, including hypoglycaemia and weight gain. 3, 4 Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates food intake and improves glycaemia in a blood glucose (BG)-dependent manner. 5 GLP-1RAs are effective at reducing HbA1c, body weight and inducing satiety. 1, 6 Unlike therapy with insulin and sulphonylureas, GLP-1RAs act by inducing glucose-dependent insulin secretion and are associated with a low risk of hypoglycaemia and weight gain. 1, [6] [7] [8] GLP-1RAs are generally well tolerated, 1 although gastrointestinal (GI) adverse events (AEs) are commonly observed across the class. 2, 9 Semaglutide (Novo Nordisk, Bagsvaerd, Denmark) is a novel GLP-1
analogue recently approved by the US Food and Drug Administration for the treatment of T2D. Its amino acid sequence is 94% homologous to that of native GLP-1, 10 and it has a half-life of~1 week, which makes it appropriate for once-weekly subcutaneous (s.c.) administration. 10, 11 SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a global phase III clinical trial programme, designed to evaluate the efficacy and safety of once-weekly s.c. semaglutide across a range of people with T2D, from those who are drug-naïve to those receiving OADs and/or insulin. [12] [13] [14] [15] [16] [17] Across the SUSTAIN trials, significantly more semaglutide-treated participants achieved HbA1c targets versus comparators, as well as clinically relevant reductions in body weight and a generally low risk of hypoglycaemia. [12] [13] [14] [15] [16] [17] In the SUSTAIN 6 trial, semaglutide also showed a 26% cardiovascular risk reduction vs placebo in participants with T2D, as measured by the composite endpoint of cardiovascular death, nonfatal myocardial infarction or non-fatal stroke. 17 The most common AEs experienced with semaglutide across the SUSTAIN programme were GI in nature. [12] [13] [14] [15] [16] [17] The SUSTAIN 7 trial evaluated once-weekly semaglutide vs once-weekly dulaglutide in people with T2D
18
; however, data from SUSTAIN 7 were not available at the time of this analysis.
In the present study, data from the SUSTAIN 1 to 5 trials [12] [13] [14] [15] [16] were analysed to evaluate the proportion of people with T2D achieving clinically relevant HbA1c targets with semaglutide while avoiding unwanted effects such as weight gain, hypoglycaemia and GI side effects.
| METHODS

| Trial design
The designs of the SUSTAIN 1 to 5 trials (NCT02054897, NCT01930188, NCT01885208, NCT02128932 and NCT02305381) have previously been reported in full [12] [13] [14] [15] [16] and are summarized in Table 1 . Briefly, adults with T2D were randomized to treatment with semaglutide or comparators for 30 or 56 weeks (Table 1) . Comparators included placebo, sitagliptin, exenatide extended release (ER) and insulin glargine (IGlar).
Semaglutide s.c. 0.5 and 1.0 mg doses were administered in all SUSTAIN trials except for SUSTAIN 3, in which only the 1.0 mg dose was administered. The two semaglutide maintenance doses were administered once weekly. Participants were followed throughout the planned treatment period, irrespective of treatment adherence. In all SUSTAIN trials, semaglutide-treated participants followed a fixed dose-escalation regimen. The semaglutide 0.5 mg maintenance dose was reached after 4 weeks of semaglutide 0.25 mg once weekly, and the semaglutide 1.0 mg maintenance dose was reached after 8 weeks:
4 weeks of semaglutide 0.25 mg once weekly, followed by 4 weeks of 0.5 mg once weekly.
Key prespecified endpoints were similar across the SUSTAIN 1 to 5 trials. [12] [13] [14] [15] [16] For all trials, the primary endpoint was change in HbA1c from baseline to end of treatment (30 or 56 weeks); the confirmatory secondary endpoint was change in body weight from baseline to end of treatment (30 or 56 weeks). Data from SUSTAIN 6 17 were not included in the present analysis because of the different design of this trial compared with others in the SUSTAIN programme; the SUSTAIN 1 to 5 trials were efficacy trials that sought to assess the maximum treatment effects of semaglutide vs comparators, whereas SUSTAIN 6 was designed to assess the safety of semaglutide in people with T2D who were at high cardiovascular risk.
| Study population
Key inclusion and exclusion criteria were generally comparable across trials. Participants in the SUSTAIN 1 to 5 trials were aged ≥18 years and diagnosed with T2D, and had baseline HbA1c <53 mmol/mol Table 1 ). The main between-trial differences related to pre-existing treatments, if any, at screening. [12] [13] [14] [15] [16] All trials were conducted in compliance with the International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. 19 The protocols were approved by local ethics committees and institutional review boards. Written informed consent was obtained from all participants before trial commencement.
| Study endpoints and assessments
The primary, prespecified, composite endpoint in the present analysis was the proportion of participants from all five trials achieving HbA1c <53 mmol/mol (7.0%) at the end of treatment (30 or 56 weeks), without weight gain and with no severe or BG-confirmed symptomatic hypoglycaemia. The secondary, post hoc composite endpoint was the proportion of participants achieving the primary composite endpoint without moderate or severe GI AEs. Other endpoints included proportions of participants achieving HbA1c <53 mmol/mol (7.0%) with either no body weight gain, no moderate or severe GI AEs, no severe or BG-confirmed hypoglycaemia, no severe hypoglycaemia, or no BG-confirmed hypoglycaemia.
Severe or BG-confirmed symptomatic hypoglycaemia was defined as an episode that is considered severe according to the American Diabetes Association classification, 20 or BG-confirmed by a plasma Abbreviations: eGFR, estimated glomerular filtration rate; ER, extended release; HbA1c, glycated haemoglobin; IGlar, insulin glargine; MEN2, multiple endocrine neoplasia type 2; MET, metformin; MTC, medullary thyroid carcinoma; NYHA, New York Heart Association; s.c., subcutaneous; SU, sulphonylurea; T2D, type 2 diabetes; TZD, thiazolidinedione.
a For Japanese participants, only those ≥20 years of age were included in the study.
b
Stable treatment was defined as having unchanged medication and dose (SUSTAIN 1-4) or AE 20% change in total daily dose (SUSTAIN 5) for at least 90 days prior to screening.
c Except short-term insulin treatment.
d
Per modification of diet in renal disease formula.
glucose value <3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. No weight gain was defined as strictly no positive change from baseline in body weight at the end of treatment.
| Analyses and statistical methods
The analyses reported in the present paper were performed on all randomized and treated participants (full analysis set) using on-treatment data without rescue medication. To avoid potential confounding of initiation of antidiabetic rescue therapies on efficacy endpoints, data collected after initiation of antidiabetic rescue therapies were excluded.
Endpoints were analysed using separate logistic regression models, with treatment, trial-specific stratification and country as fixed factors, and baseline values of HbA1c and body weight (where applicable) as covariates. Before analysis, missing HbA1c data were imputed from separate mixed models for repeated measurements, with treatment, trial-specific stratification and country and parameterspecific baseline value, all nested within visit.
3 | RESULTS
| Participants in the SUSTAIN 1 to 5 trials
Across the SUSTAIN 1 to 5 trials, 3918 participants with T2D were randomized to once-weekly s.c. semaglutide 0.5, 1.0 mg, or comparators. A total of 3899 (>99%) were exposed to an investigational product and 3565 (>90%) participants completed the trials (Table 2) .
Discontinuation rates with semaglutide were generally consistent across SUSTAIN 1 to 5. In individual trials, discontinuation rates were higher with semaglutide vs placebo (SUSTAIN 1 and 5), sitagliptin (SUSTAIN 2) and insulin glargine (SUSTAIN 4; Table 2 ). Discontinuation rates were similar between semaglutide and exenatide ER in SUSTAIN 3 ( Table 2 ). Rescue medication was administered in 99 semaglutidetreated and 185 comparator-treated participants (total of 284). The types of rescue medication administered are summarized in Table S1 .
Most participants requiring rescue medication received metformin, sulphonylureas or insulin. In the SUSTAIN 2 trial, more participants in the comparator arm received sulphonylureas than in the semaglutide arms.
In both the SUSTAIN 2 and 5 trials, more participants in the comparator arm initiated insulin or intensified their existing background insulin as rescue medication than in the semaglutide arms.
Overall, participant baseline characteristics within trials were similar across treatment groups (Table 2) , with any differences among trials reflecting the eligibility criteria. There were differences among the trials in diabetes duration, indicative of the varying intensity of antidiabetic treatments received by the participants with T2D.
| Primary composite endpoint
The proportion of participants achieving the prespecified primary composite endpoint of HbA1c <53 mmol/mol (7.0%) at end of treatment without weight gain and with no severe or BG-confirmed symptomatic hypoglycaemia was 47% to 66% with semaglutide 0.5 mg and 57% to 74% with semaglutide 1.0 mg, vs 7% to 19% with placebo and 16% to 29% with active comparators (Figure 1 ). Significantly more participants treated with semaglutide 0.5 and 1.0 mg once weekly achieved this composite endpoint vs comparators (all P < .0001; Figure 1 ).
| Post hoc composite endpoint
In the post hoc analysis, the proportion of participants achieving the composite endpoint of HbA1c <53 mmol/mol (7.0%) at end of treatment without weight gain, with no severe or BG-confirmed symptomatic hypoglycaemia, and with no moderate or severe GI AEs was 40% to 55% with semaglutide 0.5 mg and 46% to 64% with semaglutide 1.0 mg, vs 7% to 19% with placebo and 14% to 25% with active comparators (Figure 2 ). Significantly more semaglutide-treated participants achieved this composite endpoint vs comparators (all P < .0001; Figure 2 ).
| Analyses of individual components of composite endpoints
Results for the individual components of composite endpoints were mostly consistent with the findings for the primary and secondary composite endpoints. In SUSTAIN 1 to 5, the proportion of participants achieving HbA1c <53 mmol/mol (7.0%) was 58% to 74% with semaglutide 0.5 mg and 67% to 79% with semaglutide 1.0 mg, vs 11% to 25% with placebo and 36% to 40% with active comparators ( Figure 3A ). Significantly more participants achieved HbA1c targets of <53 mmol/mol (7.0%) with semaglutide 0.5 and 1.0 mg than with comparators (all P < .0001; Figure 3A ). The proportion of participants with no weight gain was 82% to 89% with semaglutide 0.5 mg and 86% to 97% with semaglutide 1.0 mg, vs 64% to 66% with placebo and 34% to 69% with active comparators (all P ≤ .0006; Figure 3B ).
The proportion of participants with no severe or BG-confirmed symptomatic hypoglycaemia was 92% to 100% with semaglutide 0.5 mg and 89% to 100% with semaglutide 1.0 mg, vs 95% to 100% with FIGURE 1 Participants achieving glycated haemoglobin (HbA1c) <53 mmol/mol (7.0%) without weight gain and with no severe or blood glucoseconfirmed symptomatic hypoglycaemia. *P < .0001 vs comparator. On-treatment without rescue medication data. The binary endpoint was analysed using a logistic regression with treatment, trial-specific stratification and country as fixed factors, and baseline HbA1c and body weight as covariates. Missing data were imputed from a mixed model for repeated measurements for change from baseline in which post-baseline data were analysed, with treatment, trial-specific stratification and country as fixed factors, and baseline value as covariate, all nested within visit. CI, confidence interval; ER, extended release; IGlar, insulin glargine; MET, metformin; n, number of participants contributing to analysis; N/A, not applicable; OAD, oral antidiabetic drug; OR, odds ratio; SU, sulphonylurea; TZD, thiazolidinedione placebo and 89% to 99% with active comparators (P < .008 for semaglutide 0.5 and 1.0 mg vs IGlar in SUSTAIN 4; Figure 3C ).
The proportion of participants with no moderate or severe GI AEs was lower with semaglutide than with comparators. The proportion of participants with no moderate/severe GI AEs was 84% to 92% with semaglutide 0.5 mg and 82% to 89% with semaglutide 1.0 mg, vs 97%
with placebo and 89% to 95% with active comparators (P < 0.01 for all comparisons except semaglutide 0.5 mg vs placebo in SUSTAIN 5; Figure 3D ).
The proportion of participants achieving HbA1c <53 mmol/mol (7.0%) with no body weight gain ranged from 49% to 66% with semaglutide 0.5 mg, and 62% to 77% with semaglutide 1.0 mg, vs 8% to 19% with placebo and 17% to 31% with active comparators. Significantly more participants achieved HbA1c targets of <53 mmol/mol (7.0%) and no weight gain with semaglutide 0.5 and 1.0 mg than with comparators (P < .0001 for all comparisons; Figure S1A ). The proportion of participants achieving HbA1c of <53 mmol/mol (7.0%) with no moderate or severe GI AEs was 51% to 62% with semaglutide 0.5 mg, and 54% to 69% with semaglutide 1.0 mg, vs 10% to 25% with placebo and 34% to 36% with active comparators (P ≤ .0002 for all comparisons; Figure S1B ).
The proportion of participants achieving HbA1c <53 mmol/mol (7.0%) without severe or BG-confirmed hypoglycaemia was 54% to 74% with semaglutide 0.5 mg, and 61% to 78% with semaglutide 1.0 mg, vs 10% to 25% with placebo and 34% to 37% with active comparators (P < .0001 for all comparisons; Figure S1C ).
The proportion of participants achieving HbA1c <53 mmol/mol (7.0%) with no severe hypoglycaemia (as defined by the American Diabetes Association) ranged from 57% to 74% with semaglutide 0.5 mg, 67%
to 78% with semaglutide 1.0 mg, vs 11% to 25% with placebo and 36% to 40% with comparators (P < .0001 for all comparisons; Figure S2A ). The proportion of participants achieving HbA1c <53 mmol/mol (7.0%) with no BG-confirmed hypoglycaemia was 54%
to 74% with semaglutide 0.5 mg, 61% to 78% with semaglutide 1.0 mg, vs 10% to 25% with placebo and 34% to 37% with active comparators (P < .0001 for all comparisons; Figure S2B ).
| DISCUSSION
When attempting to achieve adequate glycaemic control, it is important to also consider the risk of unwanted outcomes such as hypoglycaemia and weight gain. [1] [2] [3] [4] 8 The present analysis of combined data from the SUSTAIN clinical trial programme evaluated the proportion of participants who achieved the HbA1c target of <53 mmol/mol (7.0%) with no weight gain, no severe or BG-confirmed symptomatic hypoglycaemia, and no moderate or severe GI AEs. The cumulative sample size of >3900 participants represents a diverse population of participants with T2D.
Across the SUSTAIN 1 to 5 trials, approximately half to two-thirds of participants who received semaglutide 0.5 mg achieved an HbA1c concentration < 53 mmol/mol (7.0%) without weight gain and with no severe or BG-confirmed symptomatic hypoglycaemia. Up to three-
Participants achieving glycated haemoglobin (HbA1c) <53 mmol/mol (7.0%) without weight gain, with no severe or blood glucoseconfirmed symptomatic hypoglycaemia, and with no moderate or severe gastrointestinal adverse events. *P < .0001 vs comparator. On-treatment without rescue medication data. The binary endpoint was analysed using a logistic regression with treatment, trial-specific stratification, and country as fixed factors and baseline HbA1c and body weight as covariates. Missing data were imputed from a mixed model for repeated measurements for change from baseline in which post-baseline data were analysed with treatment, trial-specific stratification and country as fixed factors, and baseline value as covariate, all nested within visit. CI, confidence interval; ER, extended release; IGlar, insulin glargine; MET, metformin; n, number of participants contributing to analyses; N/A, not applicable; OAD, oral antidiabetic drug; OR, odds ratio; SU, sulphonylurea; TZD, thiazolidinedione quarters of participants achieved this outcome with semaglutide 1.0 mg. With both semaglutide doses, significantly more participants achieved this composite endpoint vs those receiving comparators.
The overall difference was mostly driven by larger proportions of participants achieving HbA1c <53 mmol/mol (7.0%) as well as by the proportions of participants experiencing no weight gain. The proportions of participants achieving HbA1c <53 mmol/mol (7.0%) with only one component of "no body weight gain", "no moderate or severe GI AEs", or "no severe or BG-confirmed symptomatic hypoglycaemia", were each significantly greater with semaglutide 0.5 and 1.0 mg vs comparators. The proportions of participants receiving semaglutide achieving HbA1c <53 mmol/mol (7.0%) with no hypoglycaemia were consistent regardless of the definition of hypoglycaemia used (severe, BG-confirmed symptomatic, or severe or BG-confirmed symptomatic).
These findings are generally consistent with those from other studies and compare favourably with published data for other GLP1RAs. 1, 6, 7, 21 For instance, a meta-analysis of seven clinical trials in participants with T2D showed that 32% to 40% of participants receiving liraglutide achieved HbA1c <53 mmol/mol (7.0%) concentrations without weight gain or hypoglycaemia, vs 8% for placebo and 8% to 25% for comparators (exenatide, IGlar, sitagliptin, sulphonylureas or thiazolidinedione). 21 A similar analysis of the AWARD clinical trial programme showed that participants with T2D receiving dulaglutide were equally likely to achieve HbA1c <53 mmol/mol (7.0%) without weight gain or hypoglycaemia as those receiving liraglutide. 22 Furthermore, the SUSTAIN 7 trial showed that participants with T2D who were treated with once-weekly semaglutide experienced superior reductions in HbA1c and body weight, in comparison with those treated with dulaglutide. 18 Across the SUSTAIN 1 to 5 trials, semaglutide was well tolerated, with a similar safety profile to that of other GLP-1RAs. [12] [13] [14] [15] [16] 23, 24 The most common AEs leading to discontinuation of semaglutide were GI in nature and, overall, most cases of GI AEs were mild or moderate and of a short duration. Proportion of subjects (%) *** *** *** *** *** *** *** *** Proportion of participants achieving glycated haemoglobin (HbA1c) <53 mmol/mol (7.0%) (A), with no weight gain (B), no severe or BG-confirmed symptomatic hypoglycaemia (C) or no moderate or severe gastrointestinal adverse events (D). *P < .0001; **P < .001; ***P < .01 vs comparator. On-treatment without rescue medication data. The binary endpoint was analysed using a logistic regression with treatment, trialspecific stratification and country as fixed factors, and baseline HbA1c and body weight as covariates. Missing data were imputed from a mixed model for repeated measurements for change from baseline in which post-baseline data were analysed with treatment, trial-specific stratification and country as fixed factors, and baseline value as covariate, all nested within visit. ER, extended release; IGlar, insulin glargine; MET, metformin; n, number of participants contributing to analysis; OAD, oral antidiabetic drug; SU, sulphonylurea; TZD, thiazolidinedione 
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